Physician profile
Tami Miller
NPI 1174164263
$851.94
in general payments reported to CMS, 2019-2025
16 companies · $472 in 2025
The $472 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $380 · 2025: $472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177.97 | 2024-2025 | |
| Lilly USA, LLC | $102.32 | 2024-2025 | Mounjaro, Zepbound, Jardiance |
| Dexcom, INC. | $69.86 | 2024-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $67.80 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $65.41 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $60.58 | 2024-2025 | |
| Glaxosmithkline, LLC. | $58.15 | 2024-2025 | Trelegy Ellipta |
| Boston Scientific Corporation | $57.42 | 2024 | Lumenis Pulse 120h |
| Astrazeneca Pharmaceuticals LP | $55.85 | 2025 | Farxiga, Airsupra |
| Xeris Pharmaceuticals, INC. | $23.62 | 2025 | Recorlev |
| Verona Pharma, INC. | $23.01 | 2025 | Ohtuvayre |
| Alnylam Pharmaceuticals INC. | $22.32 | 2024 | Amvuttra |
| Janssen Pharmaceuticals, INC | $19.28 | 2025 | Spravato |
| Coopersurgical, INC. | $16.77 | 2025 | Paragard T 380a |
| Recor Medical INC | $16.31 | 2024 | Paradise Renal Denervation System |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.27 | 2024 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tami Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.